Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: A retrospective cibmtr study

Donna E. Reece; David H. Vesole; Smriti Shrestha; Mei Jie Zhang; Waleska S. Pérez; Angela Dispenzieri; Gustavo A. Milone; Muneer Abidi; Harold Atkins; Asad Bashey; Christopher N. Bredeson; Willem Bujan Boza; César O. Freytes; Robert Peter Gale; James L. Gajewski; John Gibson; Gregory A. Hale; Shaji Kumar; Robert A. Kyle; Hillard M. Lazarus; Philip L. McCarthy; Santiago Pavlovsky; Vivek Roy; Daniel J. Weisdorf; Peter H. Wiernik; Parameswaran N. Hari

doi:10.3816/CLML.2010.n.078

Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: A retrospective cibmtr study

Donna E. Reece, David H. Vesole, Smriti Shrestha, Mei Jie Zhang, Waleska S. Pérez, Angela Dispenzieri, Gustavo A. Milone, Muneer Abidi, Harold Atkins, Asad Bashey, Christopher N. Bredeson, Willem Bujan Boza, César O. Freytes, Robert Peter Gale, James L. Gajewski, John Gibson, Gregory A. Hale, Shaji Kumar, Robert A. Kyle, Hillard M. LazarusPhilip L. McCarthy, Santiago Pavlovsky, Vivek Roy, Daniel J. Weisdorf, Peter H. Wiernik, Parameswaran N. Hari

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Introduction: Immunoglobulin D (IgD) and IgM multiple myeloma represent uncommon immunoglobulin isotypes, accounting for 2% and 0.5% of cases, respectively. Limited information is available regarding the prognosis of these isotypes, but they have been considered to have a more aggressive course than the more common immunoglobulin G (IgG) and IgA isotypes. In particular, the outcome after autologous hematopoietic stem cell transplantation (auto-HCT) has not been well defined. Patients and Methods: Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified 36 patients with IgD and 11 patients with IgM myeloma among 3578 myeloma patients who received intensive therapy and auto-HCT over a 10-year period. Results: The progression-free and overall survival probabilities at 3 years were 38% (95% CI, 21%-56%) and 69% (95% CI, 51%-84%) for IgD myeloma, and 47% (95% CI, 17%-78%) and 68% (95% CI, 36%-93%), respectively, for IgM disease. Although formal statistical analysis was limited by the small sample size, these results were comparable to those for IgG and IgA patients autografted during the same time period. Transplantation-related mortality and disease relapse/progression of myeloma were also similar for all isotypes. Conclusion: This analysis demonstrates comparable outcomes in all immunoglobulin isotypes. Therefore, auto-HCT should be offered to eligible patients with IgD and IgM myeloma.

Original language	English (US)
Pages (from-to)	458-463
Number of pages	6
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	10
Issue number	6
DOIs	https://doi.org/10.3816/CLML.2010.n.078
State	Published - Dec 2010

Bibliographical note

Funding Information:
Angela Dispenzieri has received research funding and honoraria from Celgene Corporation. Muneer Abidi has received research funding from Merck & Co., Inc.; has served as a concultant or been on an advisory/research panel for Millennium Pharmaceuticals, inc.; and has served as a member of a Speaker's Bureau for Genzyme Corporation and Millennium Pharmaceuticals, Inc. Gregory A. Hale has received research/grant funding from that American Cancer Society and the V Foundation for Cancer Research. Shaji Kumar has received research funding/clinical trial support from Celgene Corporation, Cephalon, Inc., Genzyme Corporation, Millennium Pharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation; and has served as a consultant or been on an advisory/research panel for Merck & Co., Inc. Peter H. Wiernik has recieved research funding from and served on a Speaker's Bureau for Celgene Corporation, and has served as a consultant or been on an advisory/research panel for Celgene Corporation, Novartis Pharmaceuticals Corporation, and Pfizer Inc. The remaining authors have no relevant relationships to disclose.

Keywords

Autotransplantations
IgA
IgG
Immunoglobulin isotype

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.3816/CLML.2010.n.078

OpenUrl availability

Full text

Cite this

Reece, D. E., Vesole, D. H., Shrestha, S., Zhang, M. J., Pérez, W. S., Dispenzieri, A., Milone, G. A., Abidi, M., Atkins, H., Bashey, A., Bredeson, C. N., Bujan Boza, W., Freytes, C. O., Gale, R. P., Gajewski, J. L., Gibson, J., Hale, G. A., Kumar, S., Kyle, R. A., ... Hari, P. N. (2010). Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: A retrospective cibmtr study. Clinical Lymphoma, Myeloma and Leukemia, 10(6), 458-463. https://doi.org/10.3816/CLML.2010.n.078

Reece, DE, Vesole, DH, Shrestha, S, Zhang, MJ, Pérez, WS, Dispenzieri, A, Milone, GA, Abidi, M, Atkins, H, Bashey, A, Bredeson, CN, Bujan Boza, W, Freytes, CO, Gale, RP, Gajewski, JL, Gibson, J, Hale, GA, Kumar, S, Kyle, RA, Lazarus, HM, McCarthy, PL, Pavlovsky, S, Roy, V, Weisdorf, DJ, Wiernik, PH & Hari, PN 2010, 'Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: A retrospective cibmtr study', Clinical Lymphoma, Myeloma and Leukemia, vol. 10, no. 6, pp. 458-463. https://doi.org/10.3816/CLML.2010.n.078

@article{3ca59d36759f403d91854d27482aed23,

title = "Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: A retrospective cibmtr study",

abstract = "Introduction: Immunoglobulin D (IgD) and IgM multiple myeloma represent uncommon immunoglobulin isotypes, accounting for 2% and 0.5% of cases, respectively. Limited information is available regarding the prognosis of these isotypes, but they have been considered to have a more aggressive course than the more common immunoglobulin G (IgG) and IgA isotypes. In particular, the outcome after autologous hematopoietic stem cell transplantation (auto-HCT) has not been well defined. Patients and Methods: Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified 36 patients with IgD and 11 patients with IgM myeloma among 3578 myeloma patients who received intensive therapy and auto-HCT over a 10-year period. Results: The progression-free and overall survival probabilities at 3 years were 38% (95% CI, 21%-56%) and 69% (95% CI, 51%-84%) for IgD myeloma, and 47% (95% CI, 17%-78%) and 68% (95% CI, 36%-93%), respectively, for IgM disease. Although formal statistical analysis was limited by the small sample size, these results were comparable to those for IgG and IgA patients autografted during the same time period. Transplantation-related mortality and disease relapse/progression of myeloma were also similar for all isotypes. Conclusion: This analysis demonstrates comparable outcomes in all immunoglobulin isotypes. Therefore, auto-HCT should be offered to eligible patients with IgD and IgM myeloma.",

keywords = "Autotransplantations, IgA, IgG, Immunoglobulin isotype",

author = "Reece, {Donna E.} and Vesole, {David H.} and Smriti Shrestha and Zhang, {Mei Jie} and P{\'e}rez, {Waleska S.} and Angela Dispenzieri and Milone, {Gustavo A.} and Muneer Abidi and Harold Atkins and Asad Bashey and Bredeson, {Christopher N.} and {Bujan Boza}, Willem and Freytes, {C{\'e}sar O.} and Gale, {Robert Peter} and Gajewski, {James L.} and John Gibson and Hale, {Gregory A.} and Shaji Kumar and Kyle, {Robert A.} and Lazarus, {Hillard M.} and McCarthy, {Philip L.} and Santiago Pavlovsky and Vivek Roy and Weisdorf, {Daniel J.} and Wiernik, {Peter H.} and Hari, {Parameswaran N.}",

note = "Funding Information: Angela Dispenzieri has received research funding and honoraria from Celgene Corporation. Muneer Abidi has received research funding from Merck & Co., Inc.; has served as a concultant or been on an advisory/research panel for Millennium Pharmaceuticals, inc.; and has served as a member of a Speaker's Bureau for Genzyme Corporation and Millennium Pharmaceuticals, Inc. Gregory A. Hale has received research/grant funding from that American Cancer Society and the V Foundation for Cancer Research. Shaji Kumar has received research funding/clinical trial support from Celgene Corporation, Cephalon, Inc., Genzyme Corporation, Millennium Pharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation; and has served as a consultant or been on an advisory/research panel for Merck & Co., Inc. Peter H. Wiernik has recieved research funding from and served on a Speaker's Bureau for Celgene Corporation, and has served as a consultant or been on an advisory/research panel for Celgene Corporation, Novartis Pharmaceuticals Corporation, and Pfizer Inc. The remaining authors have no relevant relationships to disclose.",

year = "2010",

month = dec,

doi = "10.3816/CLML.2010.n.078",

language = "English (US)",

volume = "10",

pages = "458--463",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "6",

}

TY - JOUR

T1 - Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation

T2 - A retrospective cibmtr study

AU - Reece, Donna E.

AU - Vesole, David H.

AU - Shrestha, Smriti

AU - Zhang, Mei Jie

AU - Pérez, Waleska S.

AU - Dispenzieri, Angela

AU - Milone, Gustavo A.

AU - Abidi, Muneer

AU - Atkins, Harold

AU - Bashey, Asad

AU - Bredeson, Christopher N.

AU - Bujan Boza, Willem

AU - Freytes, César O.

AU - Gale, Robert Peter

AU - Gajewski, James L.

AU - Gibson, John

AU - Hale, Gregory A.

AU - Kumar, Shaji

AU - Kyle, Robert A.

AU - Lazarus, Hillard M.

AU - McCarthy, Philip L.

AU - Pavlovsky, Santiago

AU - Roy, Vivek

AU - Weisdorf, Daniel J.

AU - Wiernik, Peter H.

AU - Hari, Parameswaran N.

N1 - Funding Information: Angela Dispenzieri has received research funding and honoraria from Celgene Corporation. Muneer Abidi has received research funding from Merck & Co., Inc.; has served as a concultant or been on an advisory/research panel for Millennium Pharmaceuticals, inc.; and has served as a member of a Speaker's Bureau for Genzyme Corporation and Millennium Pharmaceuticals, Inc. Gregory A. Hale has received research/grant funding from that American Cancer Society and the V Foundation for Cancer Research. Shaji Kumar has received research funding/clinical trial support from Celgene Corporation, Cephalon, Inc., Genzyme Corporation, Millennium Pharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation; and has served as a consultant or been on an advisory/research panel for Merck & Co., Inc. Peter H. Wiernik has recieved research funding from and served on a Speaker's Bureau for Celgene Corporation, and has served as a consultant or been on an advisory/research panel for Celgene Corporation, Novartis Pharmaceuticals Corporation, and Pfizer Inc. The remaining authors have no relevant relationships to disclose.

PY - 2010/12

Y1 - 2010/12

N2 - Introduction: Immunoglobulin D (IgD) and IgM multiple myeloma represent uncommon immunoglobulin isotypes, accounting for 2% and 0.5% of cases, respectively. Limited information is available regarding the prognosis of these isotypes, but they have been considered to have a more aggressive course than the more common immunoglobulin G (IgG) and IgA isotypes. In particular, the outcome after autologous hematopoietic stem cell transplantation (auto-HCT) has not been well defined. Patients and Methods: Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified 36 patients with IgD and 11 patients with IgM myeloma among 3578 myeloma patients who received intensive therapy and auto-HCT over a 10-year period. Results: The progression-free and overall survival probabilities at 3 years were 38% (95% CI, 21%-56%) and 69% (95% CI, 51%-84%) for IgD myeloma, and 47% (95% CI, 17%-78%) and 68% (95% CI, 36%-93%), respectively, for IgM disease. Although formal statistical analysis was limited by the small sample size, these results were comparable to those for IgG and IgA patients autografted during the same time period. Transplantation-related mortality and disease relapse/progression of myeloma were also similar for all isotypes. Conclusion: This analysis demonstrates comparable outcomes in all immunoglobulin isotypes. Therefore, auto-HCT should be offered to eligible patients with IgD and IgM myeloma.

AB - Introduction: Immunoglobulin D (IgD) and IgM multiple myeloma represent uncommon immunoglobulin isotypes, accounting for 2% and 0.5% of cases, respectively. Limited information is available regarding the prognosis of these isotypes, but they have been considered to have a more aggressive course than the more common immunoglobulin G (IgG) and IgA isotypes. In particular, the outcome after autologous hematopoietic stem cell transplantation (auto-HCT) has not been well defined. Patients and Methods: Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified 36 patients with IgD and 11 patients with IgM myeloma among 3578 myeloma patients who received intensive therapy and auto-HCT over a 10-year period. Results: The progression-free and overall survival probabilities at 3 years were 38% (95% CI, 21%-56%) and 69% (95% CI, 51%-84%) for IgD myeloma, and 47% (95% CI, 17%-78%) and 68% (95% CI, 36%-93%), respectively, for IgM disease. Although formal statistical analysis was limited by the small sample size, these results were comparable to those for IgG and IgA patients autografted during the same time period. Transplantation-related mortality and disease relapse/progression of myeloma were also similar for all isotypes. Conclusion: This analysis demonstrates comparable outcomes in all immunoglobulin isotypes. Therefore, auto-HCT should be offered to eligible patients with IgD and IgM myeloma.

KW - Autotransplantations

KW - IgA

KW - IgG

KW - Immunoglobulin isotype

UR - http://www.scopus.com/inward/record.url?scp=79952904942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952904942&partnerID=8YFLogxK

U2 - 10.3816/CLML.2010.n.078

DO - 10.3816/CLML.2010.n.078

M3 - Article

C2 - 21156462

AN - SCOPUS:79952904942

SN - 2152-2650

VL - 10

SP - 458

EP - 463

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 6

ER -

Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: A retrospective cibmtr study

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this